Legal & General Group Plc Sells 43,192 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Legal & General Group Plc cut its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,465 shares of the company's stock after selling 43,192 shares during the quarter. Legal & General Group Plc owned 0.07% of Dyne Therapeutics worth $1,613,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in DYN. KBC Group NV grew its holdings in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $257,000. Magnetar Financial LLC acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $263,000. E Fund Management Co. Ltd. raised its stake in Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after acquiring an additional 1,249 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at about $305,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DYN. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th. Finally, Piper Sandler cut their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $47.46.

Dyne Therapeutics Trading Up 3.3 %

DYN stock traded up $0.39 during midday trading on Thursday, hitting $12.18. 334,000 shares of the company's stock were exchanged, compared to its average volume of 2,307,573. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -3.42 and a beta of 1.21. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $47.45. The firm has a 50 day moving average price of $10.65 and a 200-day moving average price of $19.28.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 6,237 shares of company stock worth $77,760 over the last three months. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.